Aducanumab Fall-Out: An Inexpedient Use Of ‘Expedited’ Review

 
• By Michael McCaughan
Express delivery van jumps over cliff
The US FDA chose the most direct route to deliver the Biogen Alzheimer’s candidate to market, but it might not make it. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers